Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
Biogen stock last closed at $300.20, down 0.73% from the previous day, and has increased 51.23% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.41 percentage points. Biogen stock is currently +59.23% from its 52-week low of $188.54, and -6.11% from its 52-week high of $319.74.
As of Jun 2, 2023, there are 144.74M BIIB shares outstanding. The market value of BIIB is $43.45B. In the past 24 hours, 812,310 BIIB shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy BIIB shares.
In our opinion, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your purchase of stock by creating an account with eToro now.
Open eToro AccountNow that you've chosen the right brokerage, you'll need to fill out some personal information so you can invest in BIIB today.
Now that you've filled out your info on the stocks app, you need to deposit funds:
Check out the walkthrough below to see the process of transferring money into your new brokerage account.
After you have decided on the best place to buy Biogen stock, it's crucial to analyze their stock before you invest, so you can wrap your head around the risk as well as the opportunity.
WallStreetZen was built to help part-time investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on BIIB's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge BIIB's intrinsic value.
Using relative valuations metrics:
You can do more valuation analysis on BIIB's stock here.
Out of 16 Wall Street analysts who monitor BIIB, the consensus analyst rating on BIIB is a Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Brian Abrahams, a top 2% analyst from RBC Capital reiterates BIIB with a buy rating and maintains their BIIB price target from $340.00 to $340.00, on Jun 2, 2023.
Christopher Raymond, a top 24% analyst from Piper Sandler maintains BIIB with a strong buy rating and raises their BIIB price target from $346.00 to $360.00, on Jun 1, 2023.
Maintaining his Strong Buy rating, Raymond raised his price target on Biogen Inc. by 4.1%.
Given zuranolone's* "fast approaching" PDUFA date for MDD/PPD on 2023/08/05, "now is the time" to factor the drug into his model, the analyst said.
His FY 2024 - 2026 total revenue estimates for zuranolone are $200M, $570M, and $890M, respectively, Raymond detailed, citing "consultations with key opinion leader physicians in the space."
* Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). The application has been granted priority review and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of 2023/08/05. [from here]
Laura Chico, a bottom 4% analyst from Wedbush reiterates BIIB with a hold rating and maintains their BIIB price target from $263.00 to $263.00, on May 23, 2023.
Jasper Hellweg, a top 14% analyst from Argus Research maintains BIIB with a strong buy rating and raises their BIIB price target from $320.00 to $350.00, on May 11, 2023.
Geoff Meacham, a bottom 10% analyst from Bank of America maintains BIIB with a hold rating and raises their BIIB price target from $300.00 to $320.00, on May 4, 2023.
You can dig deeper into what analysts are forecasting on the Biogen stock forecast page.
Last year, BIIB earnings were $3.13B. Over the last five year, BIIB's earnings have grown by 9.04% per year. This was slower than the Drug Manufacturers - General industry average of 29.23%.
Last year, BIIB revenue was $10.10B. In the last 5 year, BIIB's revenue has gone up by -4.31% per year. This was slower than the Drug Manufacturers - General industry average of 7.67%.
Dive into BIIB's earnings and revenue performance here.
Over the last 12 months, executives and large shareholders at BIIB have sold more shares than they have bought.
Ginger Gregory, EVP Human Resources of BIIB, was the latest BIIB insider to sell. They sold $804,300.00 worth of BIIB shares on Apr 28, 2023.
Dig into more about who owns BIIB stock here.
No, Biogen doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
You have two main options:
Hit the Open button and your broker will place your order.
If you want additional help with investing in stocks on eToro, watch the helpful video below:
Now that you own some BIIB shares, you'll want to stay up-to-date on your new company.
Make a watchlist to see the latest developments about your BIIB stock.
To summarize, here are the 6 steps for buying Biogen stock:
If you need a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to watch your new investment in Biogen, add BIIB to your watchlist below.